Biliary tract cancers: From pathogenesis to endoscopic treatment

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 6, 2007, Pages 1015-1029

  Demols, Anne ^b   Maréchal, Raphaël ^b   Devière, Jacques ^b   Van Laethem, Jean Luc ^a  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

cholangiocarcinoma; etiopathogenesis; palliative and curative management

Indexed keywords

3 HYDROXYPHENYLCHLORIN; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOTOFRIN; PHOTOSENSITIZING AGENT; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIARY TRACT CANCER; BRACHYTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; ENDOSCOPIC SURGERY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PHOTODYNAMIC THERAPY; ADJUVANT THERAPY; BILE DUCT TUMOR; BILIARY TRACT SURGERY; ENDOSCOPY; INTRAHEPATIC BILE DUCT; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT SURGICAL PROCEDURES; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; ENDOSCOPY; HUMANS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 36749100860     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.09.005     Document Type: Article

References (98)

1. Ishak K.G., Anthony P.P., Sobin L.H., et al. Histological typing of tumours of the liver. WHO International Histological Classification of Tumours (1994), Springer Verlag, Berlin
2. Shaib Y.H., and El Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
4. Khan S.A., Taylor-Robinson S.D., Toledano M.B., et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 6 (2002 Dec) 806-813
5. Shaib Y.H., Davila J.A., McGlynn K., et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 40 3 (2004 Mar) 472-477
6. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 38 (1965 Feb) 241-256
7. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224 4 (1996 Oct) 463-473
8. Lim J.H., and Park C.K. Pathology of cholangiocarcinoma. Abdom Imaging 29 (2004) 540-547
9. Shaib Y.H., El-Serag H.B., Davilla J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128 3 (2005 Mar) 620-626
10. Khan S.A., Thomas H.C., Davidson B.R., et al. Cholangiocarcinoma. Lancet 366 9493 (2005 Oct 8) 1303-1314
11. Watanapa P., and Watanapa W.B. Liver fluke-associated cholangiocarcinoma. Br J Surg 89 8 (2002 Aug) 962-970
12. Scott J., Shousha S., Thomas H.C., et al. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol 73 2 (1980 Feb) 113-119
13. Sahani D., Prasad S.R., Tannabe K.K., et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging 28 1 (2003 Jan-Feb) 72-74
14. Sirica A.E. Bile duct cancer, ERBB-2, and COX-2. Sci Med 8 (2002) 268-277
15. Gores G.J. Cholangiocarcinoma: current concepts and insights. Hepatology 37 (2003) 961-969
16. Sell S., and Dunsford H.A. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 134 (1989) 1347-1363
17. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41 (2005) 5-15
18. Taylor-Robinson S.D., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48 (2001) 816-820
19. Kang Y.K., Kim W.H., and Jang J.J. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 33 (2002) 877-883
20. Ito Y., Takeda T., Sasaki Y., et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 22 (2002) 145-149
21. Sugimachi K., Aishima T., Tagushi K., et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 35 (2001) 74-79
22. Sugimachi K., Tagushi K., Aishima T., et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 14 (2001) 900-905
23. Tannapfel A., Sommerer F., Benicke M., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
24. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3 (2004) 299-307
25. Xu X., Kobayashi S., Qiao W., et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. Clin Invest 116 (2006) 1843-1852
26. Lai G.H., Zhang Z., Shen X.N., et al. ErbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129 (2005) 2047-2057
27. Ahrendt S.A., Rashid A., Chow J.T., Eisenberger C.F., Pitt H.A., and Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 7 (2000) 426-431
28. Kubicka S., Kuhnel F., Flemming P., et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 48 (2001) 403-408
29. Taniai M., Higuchi H., Burgart L.J., and Gores G.J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 123 (2002) 1090-1098
30. Caca K., Feisthammel J., Klee K., et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 97 (2002) 481-488
31. Klump B., Hsieh C.J., Dette S., et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 9 (2003) 1773-1778
32. Ashida K., Terada T., Kitamura Y., and Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 27 (1998) 974-982
33. Endo K., Ashida K., Miyake N., and Terada T. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol 193 (2001) 310-317
34. Zen Y., Sasaki M., Fujii T., et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct - an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44 (2006) 350-358
35. Yuan S.F., Li K.Z., Wang L., et al. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 11 (2005) 4661-4666
36. Müller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
37. Maroni P., Bendinelli P., Matteucci E., and Desiderio M.A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis 28 (2007) 267-279
38. Isomoto H., Kobayashi S., Werneburg N.W., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42 (2005) 1329-1338
39. Park J., Tadlock L., Gores G.J., and Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30 (1999) 1128-1133
40. Kobayashi S., Werneburg N.W., Bronk S.F., Kaufmann S.H., and Gores G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128 (2005) 2054-2065
41. Yamagiwa Y., Meng F., and Patel T. Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 78 (2006) 2494-2502
42. Haswell-Elkins M.R., Satarug S., Tsuda M., et al. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. Mutation Res 305 (1994) 241-252
43. Spirlì C., Fabris L., Duner E., et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124 (2003) 737-753
44. Jaiswal M., LaRusso N.F., Burgart L.J., and Gores G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60 (2000) 184-190
45. Jaiswal M., LaRusso N.F., Shapiro R.A., Billiar T.R., and Gores G.J. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 120 (2001) 190-199
46. Torok N.J., Higuchi H., Bronk S., and Gores G.J. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res 62 (2002) 1648-1653
47. Wang J., Torbenson M., Wang Q., Ro J.Y., and Becich M. Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 21 (2003) 117-122
48. Ishimura N., Bronk S.F., and Gores G.J. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol: Gastrointest Liver Physiol 287 (2004) G88-G95
49. Hayashi N., Yamamoto H., Hiraoka N., et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34 (2001) 638-650
50. Kiguchi K., Carbajal S., Chan K., Beltrán L., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61 (2001) 6971-6976
51. Zhang Z., Lai G.-H., and Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepathology 39 (2004) 1028-1037
52. Endo K., Yoon B., Pairojkul C., Demetris A.J., and Sirica A.E. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36 (2002) 439-450
53. Han C., and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280 (2005) 24053-24063
54. Yoon J.H., Higuchi H., Werneburg N.W., Kaufmann S.H., and Gores G.J. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122 (2002) 985-993
55. Xu L., Han C., and Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. Biol Chem 281 (2006) 33982-33996
56. Werneburg N.W., Yoon J.-H., Higuchi H., and Gores G.J. Bile acids activate EGF receptor via a TGF-α-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 285 (2003) G31-G36
57. Lai G.-H., Zhang Z., and Sirica A.E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Therapeut 2 (2003) 265-271
58. Yoon J.H., Werneburg N.W., Higuchi H., et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 15 (2002) 6500-6505
59. Park M.S., Kim T.K., Kim K.W., et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 233 1 (2004 Oct) 234-240
60. Rosch T., Meining A., Fruhmorgen S., et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 55 7 (2002 Jun) 870-876
61. de Bellis M., Fogel E.L., Sherman S., et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc 58 2 (2003 Aug) 176-182
62. Harewood G.C., Baron T.H., Stadheim L.M., et al. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 99 (2004) 1464-1469
63. Hustinx R. PET imaging in assessing gastrointestinal tumours. Radiol Clin North Am 42 6 (2004) 1123-1139
64. Slattery J.M., and Sahani D.V. What is the current state-of-the-art imaging for detecting and staging of cholangiocarcinoma?. Oncologist 11 8 (2006) 913-922
65. Kluge R., Schmidt F., Caca K., et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33 5 (2001 May) 1029-1035
66. Kato T., Tsukamoto E., Kuge Y., et al. Clinical role of (18) F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 29 8 (2002 Aug) 1047-1054
67. Jarnagin W.R., Fong Y., De Matteo R.P., et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234 4 (2001 Oct) 507-517
68. Silva M.A., Tekin K., Aytekin F., et al. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 31 5 (2005 Jun) 533-539
69. Havlik R., Shisa E., Tullo A., et al. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology 47 34 (2000 Jul-Aug) 927-931
70. Yeh C.N., Jan Y.Y., Yeh T.S., et al. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol 11 6 (2004 Jun) 606-611
71. Isaji S., Kawarada Y., Taoka H., et al. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 6 2 (1999) 108-116
72. Berdah S.V., Delpero J.R., Garcia S., et al. A western surgical experience of peripheral cholangiocarcinoma. Br J Surg 83 11 (1996 Nov) 1517-1521
73. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221 6 (1995 Jun) 788-797
74. Cherqui D., Tantawi B., Alon R., et al. Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg 130 10 (1995 Oct) 1073-1078
75. Kelley S.T., Bloomston M., Serafini F., et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 70 9 (2004 Sep) 743-748
76. Malhi H., and Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45 6 (2006 Dec) 856-867
77. Heimbach J.K., Gores G.J., Haddock M.G., et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 24 2 (2004 May) 201-207
78. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242 3 (2005 Sep) 451-458
79. Abu-Hamda E.M., and Baron T.H. Endoscopic management of cholangiocarcinoma. Semin Liver Dis 24 2 (2004) 165-175
80. Smith A.C., Dowsett J.F., Russel R.C., et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 344 8938 (1994 Dec 17) 1655-1660
81. Dowsett J.F., Vaira D., Hatfield A.R., et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 96 4 (1989 Apr) 1180-1186
82. Devière J., Baize M., de Toeuf J., et al. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 34 2 (1988 Mar-Apr) 95-101
83. Chang W.H., Kortan P., and Haber G.B. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47 (1998) 354-362
84. De Palma G.D., Galloro G., Siciliano S., et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 53 6 (2001 May) 547-553
85. Kaassis M., Boyer J., Dumas R., et al. Plastic or metal stents for malignant stricture of the common bile duct. Results of a randomized prospective study. Gastrointest Endosc 57 2 (2003 Feb) 178-182
86. Isayama H., Komatsu Y., Tsujino T., et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 53 5 (2004 May) 729-734
87. Arvanitaki M., Van Laethem J.L., Pouzere S., et al. Predictive factors for survival in patients with inoperable Klatskin tumors. Hepatogastroenterology 53 67 (2006 Jan-Feb) 21-27
88. Peters R.A., Williams S.G., Lombard M., et al. The management of high-grade hilar strictures by endoscopic insertion of self-expanding metal endoprostheses. Endoscopy 29 1 (1997 Jan) 10-16
89. Sung J. Commentary. Nat Clin Pract Gastro Hep 1 (2004) 21
90. Ortner M.A. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol 18 1 (2004 Feb) 147-154
91. Ortner M.A., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125 5 (2003 Nov) 1355-1363
92. Witzigmann H., Berr F., Ringel U., et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 244 2 (2006 Aug) 230-239
93. Czito B.G., Anscher M.S., and Willett C.G. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 20 8 (2006 Jul) 873-884 discussion 886-8, 893-5
94. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 6 (1996 Aug) 593-600
95. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 10 (2005 Apr 1) 2332-2338
96. André T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15 9 (2004 Sep) 1339-1343
97. Ogo Y., Nio Y., Yano S., et al. Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res 26 1B (2006 Jan-Feb) 763-770
98. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24 19 (2006 Jul 1) 3069-3074